ZYUS Life Sciences Corporation Announces Closing of Unsecured Loan

SASKATOON, Saskatchewan -- ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, announces that an independent director of the Company (the “Lender”) has agreed to advance a CAD$1,000,000 unsecured loan (the “Loan”) to the Company with a closing date on or about October 1, 2024 and subject to the Company filing notice of the Loan with the TSX Venture Exchange. The Loan bears interest at an annual rate of 12%, is payable on maturity, is pre-payable by the Company at any time without penalty or premium and matures on the earlier of (i) April 1, 2025, and (ii) the date the Company completes a treasury offering of its common shares and or securities convertible into common shares resulting in gross proceeds to the Company of not less than $10,000,000, or such lesser amount as the Company and the Lender may agree to in writing. The Company has granted the Lender the right to participate in such treasury offering if undertaken, but the Lender has no obligation to do so and participation is subject to approval of the TSX Venture Exchange. Read More

ZYUS Life Sciences Corporation Announces Closing of Unsecured Loan

ZYUS Life Sciences Corporation Announces Closing of Unsecured Loan

ZYUS Life Sciences Corporation Announces Closing of Unsecured Loan

ZYUS Life Sciences Corporation Announces Closing of Unsecured Loan

ZYUS Life Sciences Corporation Announces Closing of Unsecured Loan